Steve Krognes

Steve Krognes is a highly accomplished biopharmaceutical executive who recently joined the Board of Directors at Pliant Therapeutics.12 Here are some key details about his background and experience:

Professional Experience

Steve Krognes brings over 30 years of financial and corporate strategy experience in the life sciences industry.1 His career highlights include:

• Chief Financial Officer at Denali Therapeutics until his retirement in 20221
• Chief Financial Officer at Genentech, where he oversaw the integration with Roche Holding AG and InterMune1
• Global Head of Mergers and Acquisitions at Roche1
• Earlier roles in investment banking at Goldman Sachs, management consulting at McKinsey & Company, and venture capital in Scandinavia1

Current Board Positions

In addition to joining Pliant Therapeutics' board in June 2024, Mr. Krognes serves on the boards of several other companies:

• Denali Therapeutics (publicly listed)
• Guardant Health (publicly listed)
• argenx (publicly listed)
• ClavystBio (privately held, based in Singapore)12

Education

Mr. Krognes has a strong educational background in business and economics:

• M.B.A. from Harvard Business School
• B.S. in Economics from the Wharton School of the University of Pennsylvania1

Language Skills

According to his LinkedIn profile, Steve Krognes is multilingual:

• Norwegian (Bokmål): Native or bilingual proficiency
• French: Professional working proficiency
• German: Limited working proficiency4

Steve Krognes' appointment to Pliant Therapeutics' board is seen as a strategic move to leverage his extensive financial expertise and support the company's growth as it advances as a late-stage clinical company.23